February 15, 2024 News by Andrea Lobo, PhD Sudo raises $30M more to advance TYK2 inhibitor therapies to trials Sudo Biosciences has secured an additional $30 million in funding to support the development of two TYK2 inhibitor therapies for multiple sclerosis (MS) and other neurological and skin conditions ā and now is aiming to launch clinical trials later this year. With a second close of its Series…
July 27, 2023 News by Lindsey Shapiro, PhD Three MS therapies listed as WHO essential medicines For the first time, multiple sclerosis (MS) therapies have been added to the World Health Organization (WHO)ās Model Lists of Essential Medicines (EML), which names those regarded as meeting the most important needs of healthcare systems worldwide. Glatiramer acetate (sold as CopaxoneĀ with generics available), Mavenclad (cladribine)…
April 24, 2023 News by Marisa Wexler, MS AAN 2023: MS therapies don’t seem to raise pregnancy complications Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to a new analysis. A few therapies were associated with slightly elevated rates of congenital abnormalities for babies exposed to treatment during pregnancy, but small sample sizes limit being able to…
May 18, 2016 News by Patricia Silva, PhD Sanofi Genzyme and Johns Hopkins Partner on MS Research Projects into Disease Progression Sanofi GenzymeĀ announced that it entered into a research collaborationĀ withĀ the Johns Hopkins School of Medicine to betterĀ understand the underlying causes of disease progression in multiple sclerosis (MS). Sanofi GenzymeĀ has a number of research partnerships withĀ MS academic medical centers, focused on exploring the pathogenesis of MS and potential new…
April 7, 2016 News by Patricia Silva, PhD MS Patients Asked to Take Part in Survey of Risk/Benefit Considerations in Choosing Treatments The National Multiple Sclerosis Society is funding a new survey to understand how people living with multiple sclerosis (MS) weigh risks against benefits when choosing MS therapies. The survey was developed by Dr. Robert Fox, a neurologist, working with colleagues at the Cleveland Clinic and the MS patient…
March 15, 2016 News by Margarida Azevedo, MSc New MS Survey Looks into Patients’ Appraisal of Risks, Benefits When Choosing Therapies A large-scale online survey, funded by the National Multiple Sclerosis Society Ā and developed by researchers,Ā is investigating how multiple sclerosis (MS) patients perceive and evaluate the risks and benefits of available therapies. InvestigatorsĀ encourage MS patients to participate in the survey, titled āMultiple Sclerosis Risk Tolerance,ā which can be…
October 13, 2015 News by Patricia Silva, PhD Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015 A session titled āLate Breaking Newsā was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…